Skip Nav Destination
Issues
15 December 2009
-
Cover Image
Cover Image
In a targeted RNA interference screen of the human kinome, VEGFR1/Flt1 was identified as a positive regulator of Wnt/β-catenin signaling and found to be synthetic lethal in the context of aberrant Wnt activation, such as that found in colon cancer. Even in the presence of siRNA targeting VEGFR1, immunofluorescence analysis showed nuclear translocation of β-catenin upon stimulation with Wnt. Thus, VEGFR1 likely regulates Wnt signaling at the level of posttranslational modification of β-catenin and represents a potential therapeutic target for treatment of Wnt/β-catenin—addicted cancers. For further details, please see Naik and colleagues on page 7529 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
CCR Drug Update
Molecular Pathways
CCR Special Focus
Human Cancer Biology
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies; Katherine Stemke-Hale; E. Lin; Carmen Tellez; Wanleng Deng; Yennu N. Gopal; Scott E. Woodman; Tiffany C. Calderone; Zhenlin Ju; Alexander J. Lazar; Victor G. Prieto; Kenneth Aldape; Gordon B. Mills; Jeffrey E. Gershenwald
Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma
Marvaretta Stevenson; William Mostertz; Chaitanya Acharya; William Kim; Kelli Walters; William Barry; Kristin Higgins; Sascha A. Tuchman; Jeffrey Crawford; Gordana Vlahovic; Neal Ready; Mark Onaitis; Anil Potti
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Alison C. Young; Rachel A. Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A. Cairns; Dewi Astuti; Walter Gregory; Eamonn R. Maher; Margaret A. Knowles; Adrian Joyce; Peter J. Selby; Rosamonde E. Banks
Cancer Therapy: Preclinical
Transforming Growth Factor-β–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition
Cynthia C.T. Sprenger; Kathleen Haugk; Shihua Sun; Ilsa Coleman; Peter S. Nelson; Robert L. Vessella; Dale L. Ludwig; Jennifer D. Wu; Stephen R. Plymate
Imaging, Diagnosis, Prognosis
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer
Robert N. Jorissen; Peter Gibbs; Michael Christie; Saurabh Prakash; Lara Lipton; Jayesh Desai; David Kerr; Lauri A. Aaltonen; Diego Arango; Mogens Kruhøffer; Torben F. Ørntoft; Claus Lindbjerg Andersen; Mike Gruidl; Vidya P. Kamath; Steven Eschrich; Timothy J. Yeatman; Oliver M. Sieber
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
Angelica Calleri; Anna Bono; Vincenzo Bagnardi; Jessica Quarna; Patrizia Mancuso; Cristina Rabascio; Silvia Dellapasqua; Elisabetta Campagnoli; Yuval Shaked; Aron Goldhirsch; Marco Colleoni; Francesco Bertolini
The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins
M. Luana Poeta; Judith Manola; David Goldenberg; Arlene Forastiere; Joseph A. Califano; John A. Ridge; Jarrard Goodwin; Daniel Kenady; John Saunders; William Westra; David Sidransky; Wayne M. Koch
Differential Proteomics Identifies Protein Biomarkers That Predict Local Relapse of Head and Neck Squamous Cell Carcinomas
Tieneke B.M. Schaaij-Visser; A. Peggy Graveland; Sharon Gauci; Boudewijn J.M. Braakhuis; Marijke Buijze; Albert J.R. Heck; Dirk J. Kuik; Elisabeth Bloemena; C. René Leemans; Monique Slijper; Ruud H. Brakenhoff
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
Joseph A. Sparano; Lori J. Goldstein; Barrett H. Childs; Steven Shak; Diana Brassard; Sunil Badve; Frederick L. Baehner; Roberto Bugarini; Steve Rowley; Edith Perez; Lawrence N. Shulman; Silvana Martino; Nancy E. Davidson; George W. Sledge, Jr.; Robert Gray
Cancer Therapy: Clinical
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma
Gairin Dancey; John Violet; Alessandra Malaroda; Alan J. Green; Surinder K. Sharma; Roslyn Francis; Shokri Othman; Sweta Parker; John Buscombe; Natalie Griffin; Pei-San Chan; Anmol Malhotra; Nicholas Woodward; Alan Ramsay; Philip Ross; T. Andrew Lister; Peter Amlot; Richard Begent; Christopher McNamara
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
Ravi K. Amaravadi; Lynn M. Schuchter; David F. McDermott; Amy Kramer; Lydia Giles; Kristi Gramlich; Mary Carberry; Andrea B. Troxel; Richard Letrero; Katherine L. Nathanson; Michael B. Atkins; Peter J. O'Dwyer; Keith T. Flaherty
Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck
John Nemunaitis; Gary Clayman; Sanjiv S. Agarwala; William Hrushesky; James R. Wells; Charles Moore; John Hamm; George Yoo; Jose Baselga; Barbara A. Murphy; Kerstin A. Menander; Laura L. Licato; Sunil Chada; Robert D. Gibbons; Magali Olivier; Pierre Hainaut; Jack A. Roth; Robert E. Sobol; W. Jarrard Goodwin
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Han Chong Toh; Who-Whong Wang; Whay Kuang Chia; Pia Kvistborg; Li Sun; Kelly Teo; Yee Peng Phoon; Yatanar Soe; Sze Huey Tan; Siew Wan Hee; Kian Fong Foo; Simon Ong; Wen Hsin Koo; Mai-Britt Zocca; Mogens H. Claesson
Susceptibility and Prevention
Letters to the Editor
Corrections
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds